Advances in hidradenitis suppurativa
Transcript: Cardiometabolic risk in people with HS
Martina Porter
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
So there are actually several presentations on this, and it's something that I think is really needed in the literature. It's not that surprising that we're seeing, I think, increased risk of cardiometabolic events in patients with HS.
We already know that these patients have higher rates of metabolic syndrome, so they're more likely to have diabetes, hypertension, obesity for certain. And also what we know is that the patients are very inflamed. They have very high inflammatory burdens. And for other diseases that are in the same category like psoriasis and things like inflammatory arthritides, we know those patients as well have higher cardiometabolic risks. And one of the things I think that's still to be determined is whether or not treating the HS or the underlying inflammation would decrease their risk because they've thought that, I think sometimes in psoriasis, but it didn't really pan out in all studies. So it'll be to be determined in HS.
But the things that they actually did show was that there are higher risk of thrombosis in HS patients. This I think is very important when we think about safety profile for some of the upcoming medications for HS, such as JAK inhibitors, that also have a higher thrombotic risk. And for disease states, like I said, like rheumatoid arthritis, those patients actually have higher risk of clots than patients, for example, with atopic dermatitis because their underlying disease state has higher risk of thrombosis, and so when you combine that with a JAK inhibitor, you might need to be a little bit more careful. And then we're also seeing things like subclinical atherosclerosis. And there was actually a very interesting presentation on family occurrence of HS, and what they found was that patients who had a family history were actually more likely to have an increased risk of metabolic syndrome, but they didn't have a higher risk of having more severe disease, and this sort of contrasts with some of our other HS studies where we're seeing patients who have higher inflammatory burdens are the ones who have higher risk factors for cardiometabolic complications, and so it'll be very interesting, I think, to see over time how all of this pans out, but it's something definitely to be aware of as we treat these patients, that they do have higher risk of clots and cardiovascular events, and that if they have a family history, we might wanna screen them much more carefully as well.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
This content has been developed independently of the sponsor, UCB Biopharma SRL, which has had no editorial input into the content. EPG Health received funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.